| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439493 | European Journal of Cancer | 2018 | 7 Pages |
Abstract
Immune checkpoint blockade appears to be an acceptable treatment option for OPs in the setting of phase I trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
H. Herin, S. Aspeslagh, E. Castanon, V. Dyevre, A. Marabelle, A. Varga, S. Postel Vinay, J.M. Michot, V. Ribrag, A. Gazzah, R. Bahleda, O. Mir, C. Massard, A. Hollebecque, J.C. Soria, C. Baldini,